Advanced in Acute Myeloblastic Leukemia without Maturation

Dr. Stephen C. Medlin

Hematology | Oncology
Inova Health Care Services
8081 Innovation Park Dr, 
Fairfax, VA 
Accepting New Patients
Offers Telehealth
Advanced in Acute Myeloblastic Leukemia without Maturation
Inova Health Care Services
8081 Innovation Park Dr, 
Fairfax, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephen Medlin is a Hematologist and an Oncologist in Fairfax, Virginia. Dr. Medlin is rated as an Advanced provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Large-Cell Immunoblastic Lymphoma, Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Medlin is currently accepting new patients.

His clinical research consists of co-authoring 11 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in SD
Hospital Affiliations
Aurora St Lukes Medical Center
Inova Fairfax Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
DAKOTACARE
  • HMO
  • INSURANCE PLAN
HealthKeepers
  • POS
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Innovation Health
  • HMO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Primewest Health System
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

INOVA HEALTH CARE SERVICES
8081 Innovation Park Dr, Fairfax, VA 22031
Other Locations
INOVA HEALTH CARE SERVICES
3300 Gallows Rd, Falls Church, VA 22042

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drug: Belantamab Mafodotin
Study Phase: Phase 1
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Biological, Drug
Study Drugs: Polatuzumab Vedotin, Rituximab, Hyaluronidase Human, Venetoclax
Study Phase: Phase 2
View 3 Less Clinical Trials

11 Total Publications

Central Nervous System Prophylaxis Utilization in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Within a Large Community Health System.
Central Nervous System Prophylaxis Utilization in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Within a Large Community Health System.
Journal: Journal of patient-centered research and reviews
Published: July 24, 2024
Similar Doctors
Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. James K. Mccloskey
Oncology | Hematology
Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. James K. Mccloskey
Oncology | Hematology

Regional Cancer Care Associates LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (8.8 miles away)
202-444-3736
Languages Spoken:
English
See accepted insurances

James Mccloskey is an Oncologist and a Hematologist in Washington, Washington, D.c.. Dr. Mccloskey is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Bone Marrow Aspiration, and Colonoscopy.

Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Scott Rowley
Oncology | Hematology
Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Scott Rowley
Oncology | Hematology
3800 Reservoir Rd NW, 
Washington, DC 
 (8.8 miles away)
202-444-3736
Languages Spoken:
English
See accepted insurances

Scott Rowley is an Oncologist and a Hematologist in Washington, Washington, D.c.. Dr. Rowley is rated as an Elite provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Colonoscopy.

Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Danielle A. Shafer
Oncology | Hematology | Hematology Oncology
Distinguished in Acute Myeloblastic Leukemia without Maturation
Dr. Danielle A. Shafer
Oncology | Hematology | Hematology Oncology

Inova Health Care Services

3300 Gallows Rd, 
Falls Church, VA 
 (0.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Danielle Shafer is an Oncologist and a Hematologist in Falls Church, Virginia. Dr. Shafer is rated as a Distinguished provider by MediFind in the treatment of Acute Myeloblastic Leukemia without Maturation. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Aspiration, and Myringotomy. Dr. Shafer is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Medlin's expertise for a condition
ConditionClose
      View All 17 Advanced Conditions
      View All 47 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile